hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06311942, orgStudyIdInfo id: Precision AT-02, briefTitle: Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2027-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Chen Xiaoping, class: OTHER, descriptionModule briefSummary: Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. What can be done to improve the surgical prognosis of this group of patients needs to be continuously explored., conditionsModule conditions: HCC, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: HAIC plus PD-1 inhibitors plus lenvatinib, interventions name: PD-1 inhibitors plus lenvatinib, outcomesModule primaryOutcomes measure: DFS, secondaryOutcomes measure: OS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06311929, orgStudyIdInfo id: Precision AT-01, briefTitle: Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2027-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Chen Xiaoping, class: OTHER, descriptionModule briefSummary: Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. How to improve the prognosis of this group of patients is an urgent issue to be addressed., conditionsModule conditions: HCC, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: PD-1 monoclonal antibody and lenvatinib, interventions name: PD-1 monoclonal antibody, outcomesModule primaryOutcomes measure: Disease-free survival, secondaryOutcomes measure: Overall survival, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06311916, orgStudyIdInfo id: Neoadj-Net, briefTitle: Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Chen Xiaoping, class: OTHER, descriptionModule briefSummary: Primary liver cancer is one of the most common malignant tumors in the world, and more than 90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). The intermediate stage (BCLC-B) HCC is highly heterogeneous, and there is no consensus on the treatment of this stage of the tumor in Western and Eastern countries. New tools are urgently needed to guide the choice of treatment options for patients with this stage of the tumor in order to reduce the risk of postoperative recurrence and the overall survival rate., conditionsModule conditions: HCC, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 312, type: ESTIMATED, armsInterventionsModule interventions name: HAIC + Tirelizumab +lenvatinib +liver resection, interventions name: liver resection, outcomesModule primaryOutcomes measure: Disease-free survival, secondaryOutcomes measure: Safety Assessment, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06311903, orgStudyIdInfo id: 36264PR430/11/23, briefTitle: Norepinephrine in Preperiod of Hypotensive Resuscitation in Hemorrhagic Shock, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: The aim of this work was to investigate the effects of low dose of norepinephrine in preperiod of hypotensive resuscitation in hemorrhagic shock., conditionsModule conditions: Norepinephrine, conditions: Hemorrhagic Shock, conditions: Hypotensive Resuscitation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Low dose of Norepinephrine (NE), interventions name: High dose of Norepinephrine (NE), outcomesModule primaryOutcomes measure: 24 hours mortality, secondaryOutcomes measure: 28 day mortality, secondaryOutcomes measure: Incidence of acute kidney injury, secondaryOutcomes measure: Length of hospital stay, secondaryOutcomes measure: Length of intensive care unit stay, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tanta University, status: RECRUITING, city: Tanta, state: El-Gharbia, zip: 31527, country: Egypt, contacts name: Rabab M Mohamed, MD, role: CONTACT, phone: 00201069122935, email: rabmoh_30@outlook.com, contacts name: Atia G Anwar, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Ahmed A Eid, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06311890, orgStudyIdInfo id: 2023XLA141-2, briefTitle: Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2026-09-30, completionDateStruct date: 2026-09-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Xiyuan Hospital of China Academy of Chinese Medical Sciences, class: OTHER, descriptionModule briefSummary: This study aims to evaluate the clinical efficacy, safety and tolerability of a photodynamic therapy(PDT) based on a new photosensitizer, Chlorin-e6, in the treatment of moderate to severe acne. The hypothesis is that the therapy has good efficacy, safety and tolerability., conditionsModule conditions: Acne, conditions: Photodynamic Therapy, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 46, type: ESTIMATED, armsInterventionsModule interventions name: N-chlorin e6 triglumine, interventions name: acne removal surgery, outcomesModule primaryOutcomes measure: Change in Global Acne Grading System (GAGS) Relative to Baseline, otherOutcomes measure: Change in Inflammatory&non-inflammatory Lesion Counts Relative to Baseline, otherOutcomes measure: Change in Acne-specific Quality of Life Assessment Instrument（Qol-Acne）Relative to Baseline, otherOutcomes measure: Change in Numerical Rating Scale(NRS) Relative to Baseline, otherOutcomes measure: Number of participants with abnormalities of Hematological Parameters and Urine Parameters Relative to Baseline, otherOutcomes measure: Change in Adverse Reaction Management Form(AR-MF) Relative to Baseline, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Xiyuan Hospital of China Academy of Chinese Medical Sciences Organization, status: RECRUITING, city: Beijing, zip: 100091, country: China, contacts name: Huiyan Chi, doctor, role: CONTACT, phone: 13811626953, email: chihuiyan@163.com, contacts name: Yisheng Zhang, doctor, role: CONTACT, phone: 15652386117, email: llleera@126.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06311877, orgStudyIdInfo id: 6795, briefTitle: Effects of Flavor Modification for Management of Radiation Induced Dysgeusia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-02-14, completionDateStruct date: 2025-02-14, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: University of South Florida, class: OTHER, descriptionModule briefSummary: Intervention for dysgeusia in head and neck cancer patients undergoing radiation therapy. This research proposal aims to investigate potential benefits of mBerry in improving quality of life and nutritional outcome in head and neck cancer patients' post-radiation therapy. Our hypothesis is that cancer patients undergoing radiation therapy will benefit from use of miracle berry in treatment of dysgeusia., conditionsModule conditions: Dysgeusia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: mBerry, interventions name: No intervention, outcomesModule primaryOutcomes measure: 5-Point Hedonic Rating Scale, primaryOutcomes measure: Chemotherapy-induced Taste Alteration Scale (CITAS), secondaryOutcomes measure: M.D. Anderson Dysphagia Inventory (MDADI), secondaryOutcomes measure: Functional Oral Intake Scale (FOIS), otherOutcomes measure: Patients weight measurement, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06311864, orgStudyIdInfo id: PROxy240215, briefTitle: Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia With Daridorexant in Canada, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2024-09-15, completionDateStruct date: 2024-09-15, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: PeriPharm, class: OTHER, collaborators name: Idorsia Pharmaceuticals Ltd., descriptionModule briefSummary: The purpose of this observational study is to evaluate the impact of daridorexant on quality of life, work productivity and insomnia symptoms in Canadian adults suffering from insomnia., conditionsModule conditions: Insomnia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Daridorexant 50 mg, outcomesModule primaryOutcomes measure: Change from Baseline in Quality of Life, primaryOutcomes measure: Change from Baseline in Work Productivity Loss, primaryOutcomes measure: Change from Baseline in the Severity of Insomnia Symptoms, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: PROxy Network, an initiative of PeriPharm inc., city: Montreal, state: Quebec, zip: H2Y 2H4, country: Canada, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False
protocolSection identificationModule nctId: NCT06311851, orgStudyIdInfo id: PNCC140201, briefTitle: Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Pardis Noor Medical Imaging and Cancer Center, class: OTHER, descriptionModule briefSummary: Trans arterial chemoembolization (TACE) has emerged as a treatment option for chemotherapy-refractory diseases in Liver metastases. By delivering chemotherapy agents directly to the tumor site, TACE can maximize local drug concentrations and reduce systemic adverse reactions. Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor. It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A). The application of Bevacizumab during TACE has not been reported. In this study, we will evaluate the the overall survival (OS)、efficacy, and safety of the application of Bevacizumab during TACE in patients with Liver Metastases by designing an open, single-arm phase II clinical study., conditionsModule conditions: Cancer, conditions: Metastatic Cancer, conditions: Liver Metastases, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Bevacizumab, outcomesModule primaryOutcomes measure: Overall Survival Rate, primaryOutcomes measure: Objective response rate, secondaryOutcomes measure: Adverse event, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06311825, orgStudyIdInfo id: IstanbulUCDH, briefTitle: The Effect of Horticultural Therapy on Loneliness and Life Satisfaction in Elderly Adults Living in Nursing Home, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-10-31, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Istanbul University - Cerrahpasa (IUC), class: OTHER, descriptionModule briefSummary: Loneliness in elderly individuals increases with age and negatively affects individuals by decreasing life satisfaction. In recent years, horticultural therapy is a type of therapy that has developed and is added routine care of elderly individuals living in nursing homes. Social interaction, life satisfaction, feelings of success and responsibility and increase while loneliness and depression levels decrease through human-nature interaction in horticultural therapy.In our country, no study has been found on the effects of horticultural therapy on physical or mental health in elderly individuals. This research will be conducted as a randomized control group study to examine the effects of horticultural therapy on loneliness and life satisfaction in elderly individuals living in nursing homes., conditionsModule conditions: Horticultural Therapy, conditions: Loneliness, conditions: Satisfaction, Personal, conditions: Aging, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Two parallel groups randomized control study, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: Horticultural Therapy, outcomesModule primaryOutcomes measure: Loneliness Scale for Elderly, primaryOutcomes measure: Life Satisfaction Scale, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istanbul University - Cerrahpasa (IUC), city: Istanbul, state: Şişli, country: Turkey, contacts name: Hülya Bilgin, PhD, role: CONTACT, phone: 2122244986, phoneExt: 90, email: hulya.bilgin@iuc.edu.tr, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06311812, orgStudyIdInfo id: CREC 2023.683, briefTitle: Retrospective Review on Uterovaginal Anomalies, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2025-02-14, completionDateStruct date: 2025-02-14, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Chinese University of Hong Kong, class: OTHER, descriptionModule briefSummary: Review of surgical outcomes of patient who have undergone surgery for uterovaginal anomalies. Case notes of patients would be reviewed and data would be gathered for statistical analysis., conditionsModule conditions: Abnormalities Uterine, conditions: Vaginal Abnormality, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 400, type: ESTIMATED, outcomesModule primaryOutcomes measure: Incidence of re-stenosis, primaryOutcomes measure: Incidence of re-operation, primaryOutcomes measure: Number of patients with normal menstruation after operation, primaryOutcomes measure: Number of patients with sexual intercourse after operation, primaryOutcomes measure: Number of patients with post-operative infection, primaryOutcomes measure: Number of patients with pregnancy after operation, secondaryOutcomes measure: Background demographics affecting post-operative outcomes for patients with uterovaginal anomalies, secondaryOutcomes measure: Number of participants with Pre-operative factors affecting post-operative outcomes, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06311799, orgStudyIdInfo id: 2024-0102, briefTitle: Advancing Health Equity by Integrating Social-Clinical Models During Pregnancy, acronym: FIMPreg, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Geisinger Clinic, class: OTHER, collaborators name: Family Health Council of Central Pennsylvania (FHCCP), collaborators name: American Heart Association, descriptionModule briefSummary: This study is being done to find out if online references to a food management program for Women, Infants, and Children (WIC) made by doctors will get more people to enroll in WIC. Women aged 18 or older who get healthcare at Geisinger, are pregnant, and have one or more heart-related health risks (high blood pressure, diabetes, or obesity) will be asked to join this study. These women need to consent to join this study. There are four groups in this study. Group 1 will get usual care with details about WIC from their doctor. Group 2 will be sent to WIC by their doctor. Group 3 will get details about WIC from their doctor and a dietitian will talk to them about heart-healthy diets and food management. Group 4 will be sent to WIC by their doctor and a dietitian will talk to them about heart-healthy diets and food management. This study will last about 18 months and will have 200 total subjects joining at about 50 per month. Each subject will be in the study for about 6 months. Subjects will be asked to complete surveys at the start and end of the study. Some subjects will also be asked about their experience in the study team after they are done., conditionsModule conditions: Cardiovascular Diseases, conditions: Obesity, Maternal, conditions: Diabetes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: WIC Referral, interventions name: RDN Referral, outcomesModule primaryOutcomes measure: Difference in WIC enrollment, secondaryOutcomes measure: WIC retention, secondaryOutcomes measure: WIC adherence, secondaryOutcomes measure: Prenatal clinic visit adherence., secondaryOutcomes measure: RDN visit adherence, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06311773, orgStudyIdInfo id: Protocol # 24-01, briefTitle: Pivotal Trial of the Boomerang Catheter for pDVA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2026-01-15, completionDateStruct date: 2029-01-15, studyFirstPostDateStruct date: 2024-03-15, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Aveera Medical, Inc., class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to establish the safety and effectiveness of the Boomerang Catheter for percutaneous Deep Venous Arterialization (pDVA) to treat no-option Chronic Limb-Threatening Ischemia., conditionsModule conditions: Chronic Limb-Threatening Ischemia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Boomerang Catheter, outcomesModule primaryOutcomes measure: Amputation Free Survival (AFS), secondaryOutcomes measure: Technical success, secondaryOutcomes measure: Procedural success, secondaryOutcomes measure: Limb salvage, secondaryOutcomes measure: Primary patency, secondaryOutcomes measure: Primary assisted patency, secondaryOutcomes measure: Secondary patency, secondaryOutcomes measure: Target wound healing, secondaryOutcomes measure: Complete wound healing, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False